AXTI
AXT, Inc.
AXTI offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over AXTI overall, supported by stronger valuation and lower modeled downside.
AXTI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AXTI's revenue, profitability, cash flow and balance sheet are all currently strong.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AXTI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $5.95 | -86% |
| Forward | 18x | $43.54 | — |
| Fair | 23x | $9.92 | -77% |
| Expensive | 96x | $42.09 | -3.3% |
| Current | 99x | $43.54 | — |
Historical ranges are pointers, not guarantees.
AXTI's PE is in its expensive range at 99x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its fair range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AXTI in the historical PE scenario, which offers more potential upside but is not a forecast.
AXTI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for AXTI, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AXTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.40 | +445% |
| Q3 2026 | $0.44 | +$0.95 |
| Q2 2026 | $0.01 | +$0.55 |
| Q1 2026 | -$0.32 | +$0.10 |
| Q4 2025 | -$0.49 | -$0.22 |
| Q3 2025 | -$0.51 | -$0.26 |
| Q2 2025 | -$0.54 | -$0.22 |
| Q1 2025 | -$0.42 | -$0.02 |
| Q4 2024 | -$0.27 | +$0.16 |
AXTI has returned to profit: it earned $0.44 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AXTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $73.4M | +163% |
| Q2 2026 | $47.6M | +165% |
| Q1 2026 | $26.9M | +39% |
| Q4 2025 | $23M | -8.2% |
| Q3 2025 | $28M | +18% |
| Q2 2025 | $18M | -36% |
| Q1 2025 | $19.4M | -15% |
| Q4 2024 | $25.1M | +23% |
AXTI's revenue is growing: $73M last quarter, up 163% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 39% | +43 points |
| Q2 2026 | 22% | +59 points |
| Q1 2026 | -5.9% | +47 points |
| Q4 2025 | -17% | +7.9 points |
| Q3 2025 | -4% | +10 points |
| Q2 2025 | -38% | -31 points |
| Q1 2025 | -53% | -38 points |
| Q4 2024 | -25% | -7.1 points |
AXTI has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AXTI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AXTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $87.7M | +$99M |
| Q2 2026 | $3.6M | +$8.4M |
| Q1 2026 | -$13.1M | -$9.2M |
| Q4 2025 | $1.3M | +14% |
| Q3 2025 | -$11.3M | -$5M |
| Q2 2025 | -$4.9M | -949% |
| Q1 2025 | -$3.9M | +$9.3M |
| Q4 2024 | $1.1M | -48% |
AXTI's free cash flow has turned positive after six years mostly in the red: $79M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AXTI on cash flow, with more consistent year-over-year improvement.
AXTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +2.4M shares |
| 1 year | +51% | +22.2M shares |
| 3 years | +55% | +23.3M shares |
| 5 years | +54% | +23.1M shares |
| Available history | +67% | +26.4M shares |
AXTI has 66M diluted shares, up 51% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over AXTI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AXTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -9.2x | Net Cash |
| Q2 2026 | -24.4x | Net Cash |
| Q2 2023 | 93.9x | High |
| Q1 2023 | 5.5x | High |
| Q4 2022 | 2.9x | Moderate |
| Q3 2022 | 2.2x | Moderate |
| Q2 2022 | -0.4x | Net Cash |
| Q1 2022 | -0.5x | Net Cash |
AXTI has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AXTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.5 | Neutral |
| Stochastic | 15.1 | Oversold |
AXTI's weekly RSI is 43 (neutral) and its Stochastic is 15 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AXTI PE vs Technology Sector
| Metric | AXTI | Sector median | Relative |
|---|---|---|---|
| PE | 99x | 28x | 255% above |
| PE % | 83 | 35 | 48 pts above |
AXTI is trading at 99x earnings, a 255% premium to the Technology sector's median of 28x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over AXTI on valuation relative to its sector.
AXTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.3 | 27% below |
| 20 week MA | $61.9 | 30% below |
| 50 week MA | $58.0 | 25% below |
| 100 week MA | $30.5 | 43% above |
| 200 week MA | $16.8 | 159% above |
AXTI has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 159% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AXTI on trend strength, trading above more of its moving averages.
AXTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.04 | $9.64 | +139% |
| 2021 | $9.64 | $8.80 | -8.7% |
| 2022 | $8.80 | $4.40 | -50% |
| 2023 | $4.40 | $2.40 | -45% |
| 2024 | $2.40 | $2.28 | -5% |
| 2025 | $2.28 | $15.4 | +574% |
| 2026 YTD | $15.4 | $43.5 | +183% |
AXTI has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.